Research programme: erythropoietin controlled release - Avadel Pharmaceuticals
Latest Information Update: 02 Oct 2021
At a glance
- Originator Flamel Technologies
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 02 Feb 2004 Preclinical trials in Anaemia in France (unspecified route)